Telix Pharmaceuticals (TLX) Short Interest
Telix Pharmaceuticals (ASX:TLX) had 10.48% of shares reported as short positions as of 24 Aug 2026, representing 35,610,428 shares. Telix Pharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimizing damage to healthy tissues.
Short position
Telix Pharmaceuticals (ASX:TLX) has 10.48% of its shares on issue reported as short positions as of 24 Aug 2026, or about 35,610,428 shares. Over the past 30 days that figure has fallen 1.18 percentage points, and over 90 days it has fallen 4.44 percentage points. Its highest recorded short interest was 16.09% in April 2026. TLX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4TLX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Telix Pharmaceuticals
Latest TLX news
All news- Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened? - thebull.com.au
googlenews
- Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays - simplywall.st
googlenews
- Telix shares are tumbling. Is the stock finally at fair value?
motleyfool
- Could Telix Pharmaceuticals’ Equity Facility Reshape Its Funding Strategy as the Pipeline Expands?
kalkine
- Telix Pharmaceuticals (ASX:TLX) The Business Is Profitable, So Why Raise More Equity? - Stocks Down Under
googlenews
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss TLX
Start a research thread or post the first pulse update